Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles:: a prospective randomized study
Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles:: a prospective randomized study
复制标题
DOI：
10.1093/humrep/deh369
复制
发表时间：
2004-09-01
影响因子：
6.1
通讯作者：
Hugues, JN
中科院分区：
文献类型：
--
作者：
Cédrin-Durnerin, I;Grange-Dujardin, D;Hugues, JN
背景技术背景：当在卵泡晚期给药以防止LH峰时，GnRH拮抗剂诱导血清LH水平急剧下降，这可能对辅助生殖技术周期结果不利。因此，设计了一项前瞻性研究，以评估GnRH拮抗剂（西曲瑞克）给药期间补充重组人（r）LH的影响。方法：该方案包括口服避孕药的周期编程，rFSH的卵巢刺激和单剂量西曲瑞克（3 mg）的灵活给药。来自三个IVF中心的共218例患者被随机（通过密封的数据或根据女性的出生日期）接受（n=114）或不接受（n=104）从GnRH拮抗剂开始到hCG注射的每日注射rLH 75 IU。结果：唯一的显著差异是接受rLH治疗的患者的血清峰值E-2水平较高（1476+/-787vs1012 +/-659pg/ml，P
BACKGROUND: When administered in the late follicular phase to prevent an LH surge, GnRH antagonists induce a sharp decrease in serum LH levels that may be detrimental for assisted reproductive technology cycle outcome. Therefore, a prospective study was designed to assess the effects of recombinant human (r)LH supplementation during GnRH antagonist (cetrorelix) administration. METHODS: The protocol consisted of cycle programming with oral contraceptive pill, ovarian stimulation with rFSH and flexible administration of a single dose of cetrorelix (3 mg). A total of 218 patients from three IVF centres were randomized (by sealed envelops or according to woman's birth date) to receive (n=114) or not (n=104) a daily injection of rLH 75 IU from GnRH antagonist initiation to hCG injection. RESULTS: The only significant difference was a higher serum peak E-2 level in patients treated with rLH (1476+/-787 versus 1012+/-659 pg/ml, P